{"name":"MODEL","title":"","children":[{"id":"in silico","name":"in silico","presenterLast":"in silico","children":[{"id":4840,"name":4840,"title":"Transcriptomics analysis of SNX-2112 on immune and mitochodrial genes","presenterFirst":"Everardus","presenterLast":"Orlemans","keywords":"Immune response;SNX-2112;epigenetic Hsp90 inhibitor;oncometabolism","target":"HSP90","tumor":"melanoma_leukemia","sage":"discovery","pharma":"pharma","combo":"no","model":"in silico"}]},{"id":"preclinical in vitro","name":"preclinical in vitro","presenterLast":"preclinical in vitro","children":[{"id":2017,"name":2017,"title":"Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers","presenterFirst":"Shoujun","presenterLast":"Chen","keywords":"Immunotherapy;IDO1 inhibitor;Immuno-oncology;PD-1 inhibitor","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":2858,"name":2858,"title":"High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models","presenterFirst":"Charles","presenterLast":"Sinclair","keywords":"Regulatory T cells;Foxp3;Antisense oligonucleotides","target":"Foxp3","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":3699,"name":3699,"title":"Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway","presenterFirst":"Sivanandhan","presenterLast":"Dhanalakshmi","keywords":"Immunomodulation;Small molecule inhibitor","target":"PD1/L1","tumor":"renal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":6200,"name":6200,"title":"High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy","presenterFirst":"Yvonne","presenterLast":"Grobben","keywords":"Immunotherapy;Structure-based drug design;High throughput assay;Arginase","target":"arginase1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":7006,"name":7006,"title":"Small synthetic, multivalent bicyclic peptides that activate T cell costimulatory protein CD137","presenterFirst":"Peter","presenterLast":"Park","keywords":"Immunotherapy;Co-stimulation;Cancer therapy;Targeted therapy","target":"CD137","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":8167,"name":8167,"title":"Discovery of ENPP1 inhibitors as agonists of STING pathway","presenterFirst":"Sunil","presenterLast":"Sharma","keywords":"Immunomodulation;Therapeutics;Small molecule inhibitor;Cancer immunotherapy","target":"ENPP1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"preclinical xeno","name":"preclinical xeno","presenterLast":"preclinical xeno","children":[{"id":2933,"name":2933,"title":"HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition","presenterFirst":"Jie","presenterLast":"Chen","keywords":"Histone deacetylase;MDSCs;C/EBPbeta","target":"HDAC11","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3077,"name":3077,"title":"NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs","presenterFirst":"Myong","presenterLast":"Lee","keywords":"Immunotherapy","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3150,"name":3150,"title":"Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo","presenterFirst":"Fred","presenterLast":"Aswad","keywords":"Aryl hydrocarbon receptor;Immunomodulation;Small molecule inhibitor;Drug discovery","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3732,"name":3732,"title":"NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML","presenterFirst":"Marina","presenterLast":"Ciomei","keywords":"Leukemias: acute myeloid;FLT3;CSF-1R;NMS-P088","target":"CSF1-R","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4151,"name":4151,"title":"Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity","presenterFirst":"Jingsong","presenterLast":"Yang","keywords":"Cancer immunotherapy;Immunostimulation;Antigen presentation;Interferons","target":"STING","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4503,"name":4503,"title":"Impact of IDO inhibitor on tryptophan and kynurenine pathway reflected in the tumor microenvironment and highlighted using quantitative mass spectrometry imaging","presenterFirst":"Lauranne","presenterLast":"Poncelet","keywords":"Mass spectrometry;Mass spectrometry;Drug delivery","target":"IDO1","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":455,"name":455,"title":"Traf2-and Nck-interacting kinase (TNIK) inhibitor, NCB-0846, suppresses TGF-\u03b21-induced epithelial-mesenchymal transition in lung cancer","presenterFirst":"Teppei","presenterLast":"Sugano","keywords":"EMT;TGF-beta;Metastasis;Therapeutics","target":"TNIK","tumor":"lung","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5335,"name":5335,"title":"Indoximod modulates AhR-driven transcription of genes that control immune function","presenterFirst":"Erik","presenterLast":"Brincks","keywords":"Immunotherapy;Aryl hydrocarbon receptor;Immunomodulation","target":"IDO1_IDO2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5435,"name":5435,"title":"Mobilization of tumor-primed, marrow-infiltrating lymphocytes into peripheral blood with inhibitors of E-selectin or E-selectin and CXCR4","presenterFirst":"William","presenterLast":"Fogler","keywords":"E-selectin;CXCR4;T lymphocytes;Bone marrow","target":"Eselectin_CXCR4","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5676,"name":5676,"title":"eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response","presenterFirst":"Rajesh","presenterLast":"Sharma","keywords":"Immunotherapy;MNK1/2;T cell differentiation;Antitumor activity","target":"MNK1/2","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5685,"name":5685,"title":"Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response","presenterFirst":"Craig","presenterLast":"Stumpf","keywords":"Immunomodulation;T cell;MNK;eFT508","target":"MNK1/2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5745,"name":5745,"title":"Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1","presenterFirst":"Shilan","presenterLast":"Liu","keywords":"Immunotherapy;Tumor immunity;Tumor microenvironment;IDO1 inhibitor","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6224,"name":6224,"title":"The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment","presenterFirst":"Stefania","presenterLast":"Capano","keywords":"PI3K;Macrophages","target":"PI3Kg","tumor":"breast_colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6327,"name":6327,"title":"Endogenous STING inhibition induces breast cancer cell death","presenterFirst":"Hery","presenterLast":"Ratsima","keywords":"Breast cancer;Drug resistance;DNA damage;Immunotherapy","target":"STING","tumor":"breast","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":7410,"name":7410,"title":"Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development","presenterFirst":"Amanda","presenterLast":"Albert","keywords":"Immunomodulation;Innate immunity;Tyrosine kinase inhibitor;Macrophages","target":"TAM","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]}]}
